Study Reveals Mechanisms Underlying Pain Processing in Parkinson’s Disease
A novel pain-sensing brain network links pain in Parkinson’s disease to a specific region of the brain, called the subthalamic nucleus,…
Articles by José Lopes, PhD
DBS Linked to Distinct Motor and Cognitive Pathways in Brain, Finding That May Improve Its Use
The benefits of deep brain stimulation (DBS) on motor function in Parkinson’s patients are mediated by a different…
Parkinson’s Patients Show Elevated Levels of Specific Protein in Key Brain Area, Study Reports
Alterations in certain types of fat in a brain area called the substantia nigra may result in elevated levels of the GPNMB protein…
Xeomin Eases Tremor Severity, Improves Hand Function in People with Essential Tremor, Phase 2 Trial Shows
Intramuscular treatment with Xeomin (incobotulinumtoxinA) decreases tremor severity and improves hand function in patients with essential tremor of…
Pain May Be Early Detector of Parkinson’s, Study Suggests
Patients likely to have prodromal, or early, Parkinson’s disease tend to have a higher prevalence of pain, according to a new…
Cognitive, Pathological Changes Seen in Parkinson’s and Dementia with Lewy Bodies, Rat Study Shows
A newly developed rat model combining elevated levels of alpha synuclein — a key protein in both Parkinson’s disease…
Apathy Most Evident in Patients’ Behavioral and Social Habits and Linked to Depression, Study Says
Apathy is prevalent problem in Parkinson’s disease, but it is more evident in patients’ behavioral and social habits than in their…
Nutritional Supplement Boosts Benefits of Physical Rehabilitation in Patients With Parkinson’s or Parkinsonism, Study Shows
A whey protein-based nutritional supplement improved motor functions in patients with Parkinson’s or parkinsonism who were engaged in…
Opicapone Shows Motor Benefits, Eases ‘Off’ Periods for Parkinson’s Patients in Phase 3 Study
Once-daily treatment with opicapone provides continued reductions of off periods in Parkinson’s patients taking levodopa, a Phase 3 clinical study shows.
Ingrezza Eases Tardive Dyskinesia Safely and Effectively Over Long-Term, Phase 3 Trial Shows
Long-term daily use of Ingrezza (valbenazine) leads to a clinically meaningful easing of tardive dyskinesia (TD) — the repetitive and jerky…